Kehoe, S., Hook, J., Nankivell, M., Jayson, G.C., Kitchener, H., Lopes, T., et al. (2015) Primary chemoTherapy versus Primary surgery for Newly Diagnosed Advanced Ovarian Cancer (CHORUS): An Open-Label, Randomised, Controlled, Non-Inferiority Trial. Lancet, 386, 249-257.
https://doi.org/10.1016/S0140-6736(14)62223-6

has been cited by the following article:

• TITLE: Neoadjuvant Chemotherapy Followed by Surgery versus Primary Surgery in Advanced Epithelial Ovarian Cancer: A Review of Outcomes at National Institute of Cancer Research Hospital in Bangladesh

  AUTHORS: Farhana Kalam, Shahana Pervin, K. M. Nazmul Islam Joy, Johirul Islam, Annekathryn Goodman

  KEYWORDS: Neoadjuvant Chemotherapy, Interval Debulking Surgery, Primary Debulking Surgery, Cytoreductive Surgery, Epithelial Ovarian Cancer, Bangladesh

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.11, November 19, 2021

  ABSTRACT: Introduction: This study evaluated the difference in operative and clinical outcomes for patients with advanced ovarian cancer after primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in Bangladesh. Methods: Sixty patients with advanced epithelial ovarian cancer presenting to the department of Gynaecological Oncology at the National Institute of Cancer Research and Hospital were prospectively enrolled. Thirty patients underwent primary debulking surgery and thirty patients received NACT followed by IDS. Results: In the PDS and IDS groups respectively, 56.7% and 50% of patients presented with stage IIIC and 67.7% and 56.7% respectively had serious papillary type histopathology. Duration of surgery, amount of blood loss and total hospital stay were significantly lower (p in the PDS group. There was a statistically significant difference in postoperative tumor residuals between IDS and PDS patients. Complete tumor resection (R0) was obtained in 24 (80%) of IDS patients versus 13 (43.3%) PDS patients. In fifteen months of follow-up, 21 (70%) in the PDS group and 5 (16.7%) in the IDS group recurred (p = 0.021). Median progression free survival in PDS patients was twelve months while that of the IDS group was seventeen months. There was one death at 45 days in the PDS group. No other deaths were documented at fifteen months of follow-up. Conclusion: Interval debulking surgery has a more favorable outcome than primary debulking surgery on progression free survival in advanced ovarian cancer patients and permits a less aggressive surgery to be performed in Bangladesh.